GHRH receptor

GHRH receptor (also designated GHRHR) is the class B G-protein-coupled receptor expressed on anterior pituitary somatotroph cells that mediates the GH-releasing action of growth hormone-releasing hormone. The receptor is the molecular target of the synthetic GHRH-analogue compound class including tesamorelin and CJC-1295.

Definition

The GHRH receptor is a 423-amino-acid single-pass transmembrane G-protein-coupled receptor belonging to the secretin / class B GPCR family. The receptor is expressed predominantly on somatotroph cells of the anterior pituitary, with lower-level expression detected in several other tissues. Binding of native GHRH or a GHRH-analogue ligand triggers coupling to Gαs, activation of adenylate cyclase, elevation of intracellular cyclic AMP, and downstream activation of protein kinase A — the canonical cAMP-PKA signalling cascade that drives growth hormone synthesis and release from the somatotroph secretory granules.

GHRH receptor signalling is the primary endocrine input controlling pulsatile GH release from the pituitary, working in opposition to somatostatin (which suppresses GH release via the somatostatin receptor) and synergistically with ghrelin receptor (GHSR-1a) signalling. The combined GHRH + ghrelin pathway architecture is the mechanistic basis for combined-research workflows pairing GHRH analogues with growth hormone secretagogues such as ipamorelin — the two pathways converge on the same somatotroph but engage independent receptor cascades.

How GHRH receptor pharmacology is studied in peptide research

Receptor engagement is established in vitro by ligand-binding assays and cAMP-accumulation assays on pituitary or recombinant-receptor cell systems. In vivo readouts use serum GH and downstream IGF-1 measurements as the biomarker chain: receptor engagement at the pituitary triggers GH release into circulation; circulating GH engages the growth hormone receptor on peripheral tissues; downstream hepatic IGF-1 synthesis produces the IGF-1 elevation that serves as the integrated pharmacological readout.

The Jetté characterisation paper established CJC-1295 (DAC form) as a long-acting GHRH receptor agonist (PMID 15817669). Subsequent CJC-1295 work documented prolonged GH and IGF-1 secretion (PMID 16352683), pulsatile GH persistence during continuous stimulation (PMID 17018654), and GHRH-knockout mouse normalisation establishing specificity for the GHRH receptor pathway (PMID 16822960). The tesamorelin clinical trials cited in the tesamorelin entry establish the receptor’s clinical relevance in HIV-associated lipodystrophy (PMID 18057338, PMID 20554713). The Leggett work used a GHRH receptor-targeted botulinum neurotoxin construct to selectively inhibit pulsatile GH secretion, demonstrating the receptor’s role as the principal mediator of physiological GH pulse architecture (PMID 23825127).

Related terms

• Tesamorelin
• CJC-1295 No DAC
• Ipamorelin (ghrelin receptor agonist; complementary pathway)
• Growth hormone receptor (downstream of pituitary GH release)
• IGF-1 (downstream biomarker readout)
• GHRH / growth hormone-releasing hormone
• Somatotroph
• Class B GPCR / secretin receptor family

Compounds where the GHRH receptor appears in the mechanism literature

• Tesamorelin — full-length GHRH analogue acting at the GHRH receptor on pituitary somatotrophs
• CJC-1295 No DAC — modified GRF 1-29 GHRH analogue with protease resistance
• CJC-1295 + Ipamorelin blend — dual GHRH-receptor + ghrelin-receptor engagement

References

1. Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005;146(7):3052-3058. [PMID 15817669]
2. Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91(3):799-805. [PMID 16352683]
3. Alba M et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab 2006;291(6):E1290-E1294. [PMID 16822960]
4. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006;91(12):4792-4797. [PMID 17018654]
5. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357(23):2359-2370. [PMID 18057338]
6. Leggett J et al. GHRH receptor-targeted botulinum neurotoxin selectively inhibits pulsatile GH secretion in male rats. Endocrinology 2013;154(9):3305-3318. [PMID 23825127]

Glossary entries describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.